Helen Hall
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Helen Hall has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Sam M. Janes
Lungs for Living Research Centre, UCL Respiratory, University College London, London, UK
9 shared publications Sophie Tisi
Lungs for Living Research Centre, UCL Respiratory, University College London, London, UK
7 shared publicationsAnand Devaraj
Radiology, Royal Brompton and Harefield NHS Foundation Trust, London, UK
6 shared publications- Jennifer L. Dickson
Lungs for Living Research Centre, UCL Respiratory, University College London, London, UK
6 shared publications Kylie Gyertson
University College London Hospitals NHS Foundation Trust, London, UK
6 shared publicationsAllan Hackshaw
Cancer Research UK & UCL Cancer Trials Centre, University College London, London, UK
4 shared publications
Latest Publications
- Open Access
Upstaging of screen-detected lung cancers during diagnostic assessment
Introduction: Lung cancer is the leading cause of cancer-related death worldwide. Low-dose CT (LDCT) screening improves outcomes by detecting early-stage cancers as pulmonary nodules. As most are benign, diagnosing these nodules is challenging and often requires surveillance imaging. The aim of this study is to assess the frequency of cancer progression in a lung cancer screening study as measured by tumour stage (T-stage). Methods: SUMMIT is a prospective cohort study assessing implementation of lung cancer screening with LDCT in a high-risk population. Screen-detected lung cancers with clinical tumour stage cT1a–c at time of referral were included. Upstaging was defined as an increase in T-stage from referral to treatment. The date of death was obtained from the National Cancer Registration and Analysis Service. Cox proportional hazards analysis with adjustment for age, sex, Charlson Comorbidity Index and pack years was used to assess mortality between groups. Results: 390 screen-detected cancers were stage cT1a–c at time of referral. Upstaging occurred more frequently in cT1a (n=48, 56%) compared with cT1b (n=83, 38%) or cT1c (n=34, 40%), p=0.01. The proportion of part-solid nodules was similar between groups (upstaged-N=47, 27%, vs not upstaged-N=45, 21%, p=0.19). 43% of tumours increased T-stage from referral to first treatment (n=165). In participants upstaged, time from referral to treatment was longer (upstaged: 84 days, 46–298 vs not upstaged: 72 days, 43–211, p=0.04). Adjusted overall survival analyses showed an association between upstaging and mortality (HR 1.68, 95% CI 1.13 to 2.51, p=0.01). Conclusion: Tumour upstaging occurred in nearly half of early-stage cases in a lung cancer screening population. Tumour upstaging was associated with longer time to treatment and poorer outcomes in this population. Trial registration number: NCT03934866 .
Open AccessUpstaging of screen-detected lung cancers during diagnostic assessment
Introduction: Lung cancer is the leading cause of cancer-related death worldwide. Low-dose CT (LDCT) screening improves outcomes by detecting early-stage cancers as pulmonary nodules. As most are benign, diagnosing these nodules is challenging and often requires surveillance imaging. The aim of this study is to assess the frequency of cancer progression in a lung cancer screening study as measured by tumour stage (T-stage). Methods: SUMMIT is a prospective cohort study assessing implementation of lung cancer screening with LDCT in a high-risk population. Screen-detected lung cancers with clinical tumour stage cT1a–c at time of referral were included. Upstaging was defined as an increase in T-stage from referral to treatment. The date of death was obtained from the National Cancer Registration and Analysis Service. Cox proportional hazards analysis with adjustment for age, sex, Charlson Comorbidity Index and pack years was used to assess mortality between groups. Results: 390 screen-detected cancers were stage cT1a–c at time of referral. Upstaging occurred more frequently in cT1a (n=48, 56%) compared with cT1b (n=83, 38%) or cT1c (n=34, 40%), p=0.01. The proportion of part-solid nodules was similar between groups (upstaged-N=47, 27%, vs not upstaged-N=45, 21%, p=0.19). 43% of tumours increased T-stage from referral to first treatment (n=165). In participants upstaged, time from referral to treatment was longer (upstaged: 84 days, 46–298 vs not upstaged: 72 days, 43–211, p=0.04). Adjusted overall survival analyses showed an association between upstaging and mortality (HR 1.68, 95% CI 1.13 to 2.51, p=0.01). Conclusion: Tumour upstaging occurred in nearly half of early-stage cases in a lung cancer screening population. Tumour upstaging was associated with longer time to treatment and poorer outcomes in this population. Trial registration number: NCT03934866 .
- Open Access
- 10 September 2025
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 12 (1) , e003298
Differentiating clinically important interstitial lung abnormalities in lung cancer screening
Background: Interstitial lung abnormalities (ILAs) are common incidental findings in lung cancer screening (LCS). However, challenges remain in identifying clinically relevant ILAs as highlighted in a joint statement by a European multidisciplinary task force led by the European Respiratory Society (ERS). To address these challenges, we analysed ILAs identified in one of Europe’s largest LCS studies. Methods: Of 11 635 LCS individuals, 417 screen-detected ILAs were evaluated using a new visual classification system focused on traction bronchiolectasis: non-fibrotic ILA (no traction bronchiolectasis), fibrotic ILA (traction bronchiolectasis in ≤2 lobes); undiagnosed interstitial lung disease (traction bronchiolectasis in >2 lobes). Observer agreement was compared with Fleischner Society ILA classification using Cohen’s Kappa. An age, sex and smoking history-matched control group allowed the examination of associations between baseline ILA/UILD and comorbidities, forced vital capacity (FVC), hospitalisations (Student’s t-tests) and mortality (univariable and multivariable Cox proportional hazards models). Findings: Our visual ILA classification showed superior interobserver agreement (K=0.76) versus the Fleischner ILA classification (K=0.64). ILA/UILD subjects had more prevalent comorbidities, increasing (vs controls) approximately 10 years prior to ILA/UILD diagnosis. Compared with controls, mortality rates were 6-fold higher for UILD participants and 3-fold higher for fibrotic and non-fibrotic ILA subtypes. On multivariable Cox regression analysis, ILA/UILD presence (HR=4.90, 95% CI =2.36 to 10.10, p<0.001) showed stronger independent associations with mortality than baseline FVC (HR=0.98, 95% CI =0.96 to 1.00, p=0.04). Conclusion: We demonstrate a new reproducible classification of clinically important ILA/UILDs in LCS populations. We highlight that FVC shows limited associations with mortality in ILA/UILD subjects. Increased multiorgan comorbidity in ILA/UILD subjects highlights a need for comprehensive early multisystem evaluation.
- 10 September 2025
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 12 (1) , e003298
Open AccessDifferentiating clinically important interstitial lung abnormalities in lung cancer screening
Background: Interstitial lung abnormalities (ILAs) are common incidental findings in lung cancer screening (LCS). However, challenges remain in identifying clinically relevant ILAs as highlighted in a joint statement by a European multidisciplinary task force led by the European Respiratory Society (ERS). To address these challenges, we analysed ILAs identified in one of Europe’s largest LCS studies. Methods: Of 11 635 LCS individuals, 417 screen-detected ILAs were evaluated using a new visual classification system focused on traction bronchiolectasis: non-fibrotic ILA (no traction bronchiolectasis), fibrotic ILA (traction bronchiolectasis in ≤2 lobes); undiagnosed interstitial lung disease (traction bronchiolectasis in >2 lobes). Observer agreement was compared with Fleischner Society ILA classification using Cohen’s Kappa. An age, sex and smoking history-matched control group allowed the examination of associations between baseline ILA/UILD and comorbidities, forced vital capacity (FVC), hospitalisations (Student’s t-tests) and mortality (univariable and multivariable Cox proportional hazards models). Findings: Our visual ILA classification showed superior interobserver agreement (K=0.76) versus the Fleischner ILA classification (K=0.64). ILA/UILD subjects had more prevalent comorbidities, increasing (vs controls) approximately 10 years prior to ILA/UILD diagnosis. Compared with controls, mortality rates were 6-fold higher for UILD participants and 3-fold higher for fibrotic and non-fibrotic ILA subtypes. On multivariable Cox regression analysis, ILA/UILD presence (HR=4.90, 95% CI =2.36 to 10.10, p<0.001) showed stronger independent associations with mortality than baseline FVC (HR=0.98, 95% CI =0.96 to 1.00, p=0.04). Conclusion: We demonstrate a new reproducible classification of clinically important ILA/UILDs in LCS populations. We highlight that FVC shows limited associations with mortality in ILA/UILD subjects. Increased multiorgan comorbidity in ILA/UILD subjects highlights a need for comprehensive early multisystem evaluation.
- Open Access
- 6 February 2025
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 12 (1) , e002337
Uptake and 4-week outcomes of an ‘opt-out’ smoking cessation referral strategy in a London-based lung cancer screening setting
Introduction: Lung cancer screening (LCS) enables the delivery of smoking cessation interventions to a population experiencing long-term tobacco dependence, but the optimal delivery method remains unclear. Here, we report uptake and short-term outcomes of an ‘opt-out’ smoking cessation referral strategy in an LCS cohort. Methods: Individuals currently smoking tobacco who attended a face-to-face lung health check in the SUMMIT study ( NCT03934866 ) were offered very brief advice on smoking cessation and where possible, an ‘opt-out’ referral to their local stop smoking service (SSS). Aggregate data on referral outcomes were obtained from each SSS individually. Results: 33.7% (n=2090/6203) of individuals currently smoking tobacco consented to a practitioner-made ‘opt-out’ smoking cessation referral. 42.7% (n=893/2090) of these individuals resided in boroughs where SSS were not present or required self-referral. Males (adjusted OR (aOR) 1.16), younger individuals (55–59: aOR 1.70, 60–64: aOR 1.71 and 65–69: aOR 1.78) and those of ethnic minority backgrounds (Asian: aOR 1.31, Black: aOR 1.71 and Mixed: aOR 1.72) were more likely to consent, while individuals from the most deprived socioeconomic quintile were less likely to do so (aOR 0.65). High level of motivation to quit within a defined time frame (aOR 1.92), previous quit attempts in the past 12 months (1–4: aOR 1.65 and ≥5: aOR 1.54) and time to first cigarette of ≤60 min (<5: aOR 2.07, 6–30: aOR 1.55 and 31–60: aOR 1.56) were measures of tobacco dependence associated with a higher likelihood of providing consent. Outcomes were available for 742 referrals. An appointment with the service was accepted by 47.3% (n=351/742) of individuals, following which 65.5% (n=230/351) set a quit date. The 4-week quit rate among those setting a quit date and all individuals referred was 57.4% (n=132/230) and 17.8% (n=132/742), respectively. Conclusion: A proactive, ‘opt-out’ smoking cessation referral strategy for individuals currently smoking tobacco who interact with an LCS programme may be beneficial.
- 6 February 2025
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 12 (1) , e002337
Open AccessUptake and 4-week outcomes of an ‘opt-out’ smoking cessation referral strategy in a London-based lung cancer screening setting
Introduction: Lung cancer screening (LCS) enables the delivery of smoking cessation interventions to a population experiencing long-term tobacco dependence, but the optimal delivery method remains unclear. Here, we report uptake and short-term outcomes of an ‘opt-out’ smoking cessation referral strategy in an LCS cohort. Methods: Individuals currently smoking tobacco who attended a face-to-face lung health check in the SUMMIT study ( NCT03934866 ) were offered very brief advice on smoking cessation and where possible, an ‘opt-out’ referral to their local stop smoking service (SSS). Aggregate data on referral outcomes were obtained from each SSS individually. Results: 33.7% (n=2090/6203) of individuals currently smoking tobacco consented to a practitioner-made ‘opt-out’ smoking cessation referral. 42.7% (n=893/2090) of these individuals resided in boroughs where SSS were not present or required self-referral. Males (adjusted OR (aOR) 1.16), younger individuals (55–59: aOR 1.70, 60–64: aOR 1.71 and 65–69: aOR 1.78) and those of ethnic minority backgrounds (Asian: aOR 1.31, Black: aOR 1.71 and Mixed: aOR 1.72) were more likely to consent, while individuals from the most deprived socioeconomic quintile were less likely to do so (aOR 0.65). High level of motivation to quit within a defined time frame (aOR 1.92), previous quit attempts in the past 12 months (1–4: aOR 1.65 and ≥5: aOR 1.54) and time to first cigarette of ≤60 min (<5: aOR 2.07, 6–30: aOR 1.55 and 31–60: aOR 1.56) were measures of tobacco dependence associated with a higher likelihood of providing consent. Outcomes were available for 742 referrals. An appointment with the service was accepted by 47.3% (n=351/742) of individuals, following which 65.5% (n=230/351) set a quit date. The 4-week quit rate among those setting a quit date and all individuals referred was 57.4% (n=132/230) and 17.8% (n=132/742), respectively. Conclusion: A proactive, ‘opt-out’ smoking cessation referral strategy for individuals currently smoking tobacco who interact with an LCS programme may be beneficial.
- Open Access
- 26 July 2022
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 60 (6) , 2200795
Detection of COPD in the SUMMIT Study lung cancer screening cohort using symptoms and spirometry
Background: COPD is a major comorbidity in lung cancer screening (LCS) cohorts, with a high prevalence of undiagnosed COPD. Combining symptom assessment with spirometry in this setting may enable earlier diagnosis of clinically significant COPD and facilitate increased understanding of lung cancer risk in COPD. In this study, we wished to understand the prevalence, severity, clinical phenotype and lung cancer risk of individuals with symptomatic undiagnosed COPD in a LCS cohort.Methods: 16 010 current or former smokers aged 55–77 years attended a lung health check as part of the SUMMIT Study. A respiratory consultation and spirometry were performed alongside LCS eligibility assessment. Those with symptoms, no previous COPD diagnosis and airflow obstruction were labelled as undiagnosed COPD. Baseline low-dose computed tomography (LDCT) was performed in those at high risk of lung cancer (PLCOm2012score ≥1.3% and/or meeting USPSTF 2013 criteria).Results: Nearly one in five (19.7%) met criteria for undiagnosed COPD. Compared with those previously diagnosed, those undiagnosed were more likely to be male (59.1%versus53.2%; pversus47.6%; pversus68.4%; pversus77.9%; p<0.001) than those with known COPD. Multivariate analysis demonstrated that airflow obstruction was an independent risk factor for lung cancer risk on baseline LDCT (adjusted OR 2.74, 95% CI 1.73–4.34; p<0.001), with a high risk seen in those with undiagnosed COPD (adjusted OR 2.79, 95% CI 1.67–4.64; p<0.001).Conclusions: Targeted case-finding within LCS detects high rates of undiagnosed symptomatic COPD in those most at risk. Individuals with undiagnosed COPD are at high risk for lung cancer.
- 26 July 2022
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 60 (6) , 2200795
Open AccessDetection of COPD in the SUMMIT Study lung cancer screening cohort using symptoms and spirometry
Background: COPD is a major comorbidity in lung cancer screening (LCS) cohorts, with a high prevalence of undiagnosed COPD. Combining symptom assessment with spirometry in this setting may enable earlier diagnosis of clinically significant COPD and facilitate increased understanding of lung cancer risk in COPD. In this study, we wished to understand the prevalence, severity, clinical phenotype and lung cancer risk of individuals with symptomatic undiagnosed COPD in a LCS cohort.Methods: 16 010 current or former smokers aged 55–77 years attended a lung health check as part of the SUMMIT Study. A respiratory consultation and spirometry were performed alongside LCS eligibility assessment. Those with symptoms, no previous COPD diagnosis and airflow obstruction were labelled as undiagnosed COPD. Baseline low-dose computed tomography (LDCT) was performed in those at high risk of lung cancer (PLCOm2012score ≥1.3% and/or meeting USPSTF 2013 criteria).Results: Nearly one in five (19.7%) met criteria for undiagnosed COPD. Compared with those previously diagnosed, those undiagnosed were more likely to be male (59.1%versus53.2%; pversus47.6%; pversus68.4%; pversus77.9%; p<0.001) than those with known COPD. Multivariate analysis demonstrated that airflow obstruction was an independent risk factor for lung cancer risk on baseline LDCT (adjusted OR 2.74, 95% CI 1.73–4.34; p<0.001), with a high risk seen in those with undiagnosed COPD (adjusted OR 2.79, 95% CI 1.67–4.64; p<0.001).Conclusions: Targeted case-finding within LCS detects high rates of undiagnosed symptomatic COPD in those most at risk. Individuals with undiagnosed COPD are at high risk for lung cancer.
- Open Access
Telephone risk-based eligibility assessment for low-dose CT lung cancer screening
Eligibility for lung cancer screening (LCS) requires assessment of lung cancer risk, based on smoking history alongside demographic and medical factors. Reliance on individual face-to-face eligibility assessment risks inefficiency and costliness. The SUMMIT Study introduced a telephone-based lung cancer risk assessment to guide invitation to face-to-face LCS eligibility assessment, which significantly increased the proportion of face-to-face attendees eligible for LCS. However, levels of agreement between phone screener and in-person responses were lower in younger individuals and minority ethnic groups. Telephone-based risk assessment is an efficient way to optimise selection for LCS appointments but requires further iteration to ensure an equitable approach.
Open AccessTelephone risk-based eligibility assessment for low-dose CT lung cancer screening
Eligibility for lung cancer screening (LCS) requires assessment of lung cancer risk, based on smoking history alongside demographic and medical factors. Reliance on individual face-to-face eligibility assessment risks inefficiency and costliness. The SUMMIT Study introduced a telephone-based lung cancer risk assessment to guide invitation to face-to-face LCS eligibility assessment, which significantly increased the proportion of face-to-face attendees eligible for LCS. However, levels of agreement between phone screener and in-person responses were lower in younger individuals and minority ethnic groups. Telephone-based risk assessment is an efficient way to optimise selection for LCS appointments but requires further iteration to ensure an equitable approach.
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 2202
Abstract 2202: Contiguous airway sampling for basal cell isolation
Introduction: Airway basal cells isolated from histologically normal epithelium in current and former smokers demonstrate a significantly higher mutation burden than those in never-smokers. However, a proportion of basal cells with lower (“near normal”) mutation burden are observed, which show preferential expansion in response to smoking cessation(1). We believe this expansion represents a “cancer protective” process, reducing the risk of future malignancy. However, mechanisms determining the dynamic balance of high versus low mutant basal cells throughout the bronchial tree are unclear. We have developed protocols that enable systematic scanning of airway epithelium in resected lung specimens, through which we aim to elucidate the mutation burden and spatial clonal architecture across contiguous regions of normal epithelium through the bronchial tree. Study design: 5-10 current or former smokers undergoing curative lobectomy for peripheral lung cancer with histologically normal airways will be consented to the study. To date, two participants have donated their samples. Fresh lobectomies were collected at the point of resection and kept on wet ice until pathological examination. All samples undergo examination within 1 hour of resection. The lobe is orientated, and the tumour and segmental bronchi identified. A sterile metal cannula is inserted through the airway lumen and sterile pathology scissors are used to carefully isolate the airways from the surrounding parenchyma. Upon macro-dissection, airway branches are immediately placed into transport media containing antibiotics. Samples are gently washed using transport media to remove residual blood, then sectioned into 1 cm3 segments, which are orientated, embedded and frozen in room-temperature Optimal Cutting Temperature compound. An 8 μM section is cut and stained with haematoxylin and eosin from each block immediately after a “full-face” tissue confirmation is observed.These will be used as guiding slides for laser capture microdissection of the regions of epithelium prior to downstream sequencing pathway. Conclusion: We have developed a pathological approach in which we can define somatic mutations in normal epithelium along the bronchial tree. We will use these data to determine basal cell clonal relationships and interpret these in a spatial context, creating a more detailed map of the smoking-induced changes that occur in the airway epithelium and how these may contribute to early carcinogenesis. References1.Yoshida K, Gowers KHC, Lee-Six H, Chandrasekharan DP, Coorens T, Maughan EF, et al. Tobacco smoking and somatic mutations in human bronchial epithelium. Nature. 2020;578(7794):266-72. Citation Format: Kate E. Davies, Helen Hall, Zoe Frazer, Kate Gowers, David Moore, Fleur Monk, Moritz J. Przybilla, Peter J. Campbell, Sam M. Janes. Contiguous airway sampling for basal cell isolation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2202.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 2202
Open AccessAbstract 2202: Contiguous airway sampling for basal cell isolation
Introduction: Airway basal cells isolated from histologically normal epithelium in current and former smokers demonstrate a significantly higher mutation burden than those in never-smokers. However, a proportion of basal cells with lower (“near normal”) mutation burden are observed, which show preferential expansion in response to smoking cessation(1). We believe this expansion represents a “cancer protective” process, reducing the risk of future malignancy. However, mechanisms determining the dynamic balance of high versus low mutant basal cells throughout the bronchial tree are unclear. We have developed protocols that enable systematic scanning of airway epithelium in resected lung specimens, through which we aim to elucidate the mutation burden and spatial clonal architecture across contiguous regions of normal epithelium through the bronchial tree. Study design: 5-10 current or former smokers undergoing curative lobectomy for peripheral lung cancer with histologically normal airways will be consented to the study. To date, two participants have donated their samples. Fresh lobectomies were collected at the point of resection and kept on wet ice until pathological examination. All samples undergo examination within 1 hour of resection. The lobe is orientated, and the tumour and segmental bronchi identified. A sterile metal cannula is inserted through the airway lumen and sterile pathology scissors are used to carefully isolate the airways from the surrounding parenchyma. Upon macro-dissection, airway branches are immediately placed into transport media containing antibiotics. Samples are gently washed using transport media to remove residual blood, then sectioned into 1 cm3 segments, which are orientated, embedded and frozen in room-temperature Optimal Cutting Temperature compound. An 8 μM section is cut and stained with haematoxylin and eosin from each block immediately after a “full-face” tissue confirmation is observed.These will be used as guiding slides for laser capture microdissection of the regions of epithelium prior to downstream sequencing pathway. Conclusion: We have developed a pathological approach in which we can define somatic mutations in normal epithelium along the bronchial tree. We will use these data to determine basal cell clonal relationships and interpret these in a spatial context, creating a more detailed map of the smoking-induced changes that occur in the airway epithelium and how these may contribute to early carcinogenesis. References1.Yoshida K, Gowers KHC, Lee-Six H, Chandrasekharan DP, Coorens T, Maughan EF, et al. Tobacco smoking and somatic mutations in human bronchial epithelium. Nature. 2020;578(7794):266-72. Citation Format: Kate E. Davies, Helen Hall, Zoe Frazer, Kate Gowers, David Moore, Fleur Monk, Moritz J. Przybilla, Peter J. Campbell, Sam M. Janes. Contiguous airway sampling for basal cell isolation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2202.
- 10 February 2022
- Published by Elsevier in Lung Cancer
- Vol. 165, S69
The CLIMB study: immune checkpoint inhibitor effects on lung airway mutational burden
- 10 February 2022
- Published by Elsevier in Lung Cancer
- Vol. 165, S69
The CLIMB study: immune checkpoint inhibitor effects on lung airway mutational burden
- 10 February 2022
- Published by Elsevier in Lung Cancer
- Vol. 165, S20
Quality assurance of radiology reporting in lung cancer screening: the role of a radiology review meeting
- 10 February 2022
- Published by Elsevier in Lung Cancer
- Vol. 165, S20
Quality assurance of radiology reporting in lung cancer screening: the role of a radiology review meeting
- Open Access
Association between time-to-treatment and outcomes in non-small cell lung cancer: a systematic review
Background National targets for timely diagnosis and management of a potential cancer are driven in part by the perceived risk of disease progression during avoidable delays. However, it is unclear to what extent time-to-treatment impacts prognosis for patients with non-small cell lung cancer, with previous reviews reporting mixed or apparently paradoxical associations. This systematic review focuses on potential confounders in order to identify particular patient groups which may benefit most from timely delivery of care. Methods Medline, EMBASE and Cochrane databases were searched for publications between January 2012 and October 2020, correlating timeliness in secondary care pathways to patient outcomes. The protocol is registered with PROSPERO (the International Prospective Register of Systematic Reviews; ID 99239). Prespecified factors (demographics, performance status, histology, stage and treatment) are examined through narrative synthesis. Results Thirty-seven articles were included. All but two were observational. Timely care was generally associated with a worse prognosis in those with advanced stage disease (6/8 studies) but with better outcomes for patients with early-stage disease treated surgically (9/12 studies). In one study, patients with squamous cell carcinoma referred for stereotactic ablative radiotherapy benefited more from timely care, compared with patients with adenocarcinoma. One randomised controlled trial supported timeliness as being advantageous in those with stage I–IIIA disease. Conclusion There are limitations to the available evidence, but observed trends suggest timeliness to be of particular importance in surgical candidates. In more advanced disease, survival trends are likely outweighed by symptom burden, performance status or clinical urgency dictating timeliness of treatment.
Open AccessAssociation between time-to-treatment and outcomes in non-small cell lung cancer: a systematic review
Background National targets for timely diagnosis and management of a potential cancer are driven in part by the perceived risk of disease progression during avoidable delays. However, it is unclear to what extent time-to-treatment impacts prognosis for patients with non-small cell lung cancer, with previous reviews reporting mixed or apparently paradoxical associations. This systematic review focuses on potential confounders in order to identify particular patient groups which may benefit most from timely delivery of care. Methods Medline, EMBASE and Cochrane databases were searched for publications between January 2012 and October 2020, correlating timeliness in secondary care pathways to patient outcomes. The protocol is registered with PROSPERO (the International Prospective Register of Systematic Reviews; ID 99239). Prespecified factors (demographics, performance status, histology, stage and treatment) are examined through narrative synthesis. Results Thirty-seven articles were included. All but two were observational. Timely care was generally associated with a worse prognosis in those with advanced stage disease (6/8 studies) but with better outcomes for patients with early-stage disease treated surgically (9/12 studies). In one study, patients with squamous cell carcinoma referred for stereotactic ablative radiotherapy benefited more from timely care, compared with patients with adenocarcinoma. One randomised controlled trial supported timeliness as being advantageous in those with stage I–IIIA disease. Conclusion There are limitations to the available evidence, but observed trends suggest timeliness to be of particular importance in surgical candidates. In more advanced disease, survival trends are likely outweighed by symptom burden, performance status or clinical urgency dictating timeliness of treatment.
- 1 March 2021
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 16 (3) , S473-S474
P41.04 The SUMMIT Study: Pulmonary Nodule and Incidental Findings in the First 10,000 Participants of a Population-Based Low-Dose CT Screening Study
- 1 March 2021
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 16 (3) , S473-S474
P41.04 The SUMMIT Study: Pulmonary Nodule and Incidental Findings in the First 10,000 Participants of a Population-Based Low-Dose CT Screening Study